ANAHEIM, Calif., May 20, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the passage byits shareholders of the six proposals considered during the Company's annual meeting on May 19, 2011.
Shareholders voted in favor of the following:
"On behalf of the board of directors, management and employees of Questcor, I would like to thank our shareholders for their support of the proposals considered at this year's annual meeting. We believe that our shareholders' approval of the proposals to add shares to our Equity Incentive Award Plan and our Employee Stock Purchase Plan will play a key role in Questcor's ability to attract top talent to the organization and continue to generate strong returns for our shareholders," said Don M. Bailey, President and CEO of Questcor.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:
For more information, please visit www.questcor.com or www.acthar.com.
SOURCE Questcor Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All